Lexicon Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1997
Net Income	-193.58	-177.12	-101.94	-87.76	-58.57	130.13	Upgrade
Depreciation & Amortization	0.59	0.55	0.43	0.29	2.93	3.65	Upgrade
Share-Based Compensation	15.23	14.34	11.52	10.58	13.27	14.22	Upgrade
Other Operating Activities	-7.65	0.33	1.15	-10.13	-100.6	-34.2	Upgrade
Operating Cash Flow	-185.41	-161.9	-88.85	-87.02	-142.97	113.81	Upgrade
Capital Expenditures	-0.22	-0.47	-1.33	-1.22	10.93	-0.07	Upgrade
Acquisitions	0	0	0	0	160.39	0	Upgrade
Change in Investments	-172.04	-49.47	-69.75	3.33	209.45	-155.79	Upgrade
Investing Cash Flow	-172.26	-49.94	-71.08	2.11	380.76	-155.86	Upgrade
Share Issuance / Repurchase	137.18	138	93.34	34.41	68.94	-0.94	Upgrade
Debt Issued / Paid	49.96	49.96	48.87	-11.7	-216.58	-1.29	Upgrade
Other Financing Activities	241.03	-	-	-	-	-	Upgrade
Financing Cash Flow	428.17	187.96	142.21	22.71	-147.64	-2.23	Upgrade
Net Cash Flow	70.49	-23.88	-17.72	-62.2	90.15	-44.27	Upgrade
Free Cash Flow	-185.64	-162.37	-90.18	-88.24	-132.04	113.74	Upgrade
Free Cash Flow Margin	-8032.71%	-13485.63%	-64875.54%	-29610.07%	-550.29%	35.31%	Upgrade
Free Cash Flow Per Share	-0.76	-0.73	-0.54	-0.61	-1.19	1.07	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).